RANI (Rani Therapeutics Holdings) 3-Year Share Buyback Ratio: -56.90% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RANI Rani Therapeutics Holdings Inc RANI
30 GF Score
Price $0.80
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings 3-Year Share Buyback Ratio?

Rani Therapeutics Holdings RANI -0.50% 30 3-Year Share Buyback Ratio is -56.90 as of Jun. 2026. GuruFocus rates RANI with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,190 Biotechnology companies, Rani Therapeutics Holdings ranks worse than 85.13% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Rani Therapeutics Holdings's current 3-Year Share Buyback Ratio was -56.90%.

The historical rank and industry rank for Rani Therapeutics Holdings's 3-Year Share Buyback Ratio or its related term are showing as below:

RANI' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -56.9   Med: -15.35   Max: -10.4
Current: -56.9

During the past 7 years, Rani Therapeutics Holdings's highest 3-Year Share Buyback Ratio was -10.40%. The lowest was -56.90%. And the median was -15.35%.

RANI's 3-Year Share Buyback Ratio is ranked worse than
85.13% of 1190 companies
in the Biotechnology industry
Industry Median: -11.75 vs RANI: -56.90

Rani Therapeutics Holdings (NAS:RANI) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Rani Therapeutics Holdings 3-Year Share Buyback Ratio Related Terms


RANI vs ONCY, ALDX, COYA: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Rani Therapeutics Holdings's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rani Therapeutics Holdings 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's 3-Year Share Buyback Ratio falls into.


RANI
30GF Score
Rani Therapeutics Holdings Inc RANI
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -56.90 mean?
Rani Therapeutics Holdings (RANI) has a 3-Year Share Buyback Ratio of -56.90 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Rani Therapeutics Holdings and its competitors. According to the industry distribution chart, Rani Therapeutics Holdings ranks #1013 out of 1190 companies in the Biotechnology industry, placing it in the top 85.1%.
Is Rani Therapeutics Holdings' 3-Year Share Buyback Ratio too high?
Rani Therapeutics Holdings' current 3-Year Share Buyback Ratio is -56.90. Based on the distribution chart, Rani Therapeutics Holdings ranks #1013 out of 1190 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rani Therapeutics Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' 3-Year Share Buyback Ratio compare to ONCY and ALDX?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #1013 out of 1190 companies for 3-Year Share Buyback Ratio. This places Rani Therapeutics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current 3-Year Share Buyback Ratio is -56.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current 3-Year Share Buyback Ratio of -56.90. The current 3-Year Share Buyback Ratio is -56.90. Rani Therapeutics Holdings' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current 3-Year Share Buyback Ratio is -56.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
30GF Score

Get the complete analysis for RANI

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.80
Price